Immorna
Business Services · North Carolina, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
635 Davis Dr Ste 400, Morrisville, North...Website
www.immorna.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Immorna
Immorna is a rapidly expanding biotechnology company, focusing on the development of mRNA-based therapeutics and vaccines. Immorna is utilizing multiple mRNA platforms, including conventional, self-replicating and circular mRNA. Since its founding in 2019, Immorna has built a robust CMC platform for mRNA synthesis, purification, and analytical testing that is well suited for clinical and commercial development. In addition, with its state-of-the-art screening tools, Immorna has developed an arsenal of mRNA delivery vehicles, including polymers and lipid nanoparticles featuring multiple proprietary ionizable cationic lipids suitable for intramuscular, intravenous and tissue-targeting delivery. Immorna has a growing intellectual property portfolio and a diverse mRNA development pipeline spanning cancer immunotherapy, infectious diseases, rare genetic diseases, and medical cosmetology, and quickly advancing its oncology and infectious disease drug candidates into their clinical stages.Explore more
Immorna Org Chart
ZG
Chief Technology Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immorna your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Immorna recently announced quarterly report
Check if Immorna has recently received funding, and reach out quickly before it becomes old news!
Click to see if Immorna had a recent Job posting/layoffs
Immorna, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Immorna launches new products
Congratulate Masked Content for being promoted to Masked Content at Immorna
Funding: Get notified immidiatlly once Immorna has new funding data
Check out if Immorna is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Immorna as Masked Content
Find 2 more new buyers
Compare Similar Companies to Immorna
Compare insights from companies similar to Immorna, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immorna is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Immorna is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Immorna.
Immorna Tech Stack
A closer look at the technologies used by Immorna
See more technologies
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Immorna News & Media
Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors
MORRISVILLE, NC., July 8, 2024 /PRNewswire/ -- Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics and vaccines, announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for JCXH-211 intravenous (IV), a novel, first-in-class self-replicating mRNA (srRNA) encoding the engineered human interleukin (IL)-12 protein. The IND clearance
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immorna
Sign Up For FreeTo access detailed company insights
Immorna is a rapidly expanding biotechnology company, focusing on the development of mRNA-based therapeutics and vaccines. Immorna is utilizing multiple mRNA platforms, including conventional, self-replicating and circular mRNA. Since its founding in 2019, Immorna has built a robust CMC platform for mRNA synthesis, purification, and analytical test... Read More
